Literature DB >> 21210950

Tissue factor pathway inhibitor and bacterial infection.

S A Maroney1, A E Mast.   

Abstract

See also van den Boogaard FE, Brands X, Schultz MJ, Levi M, Roelofs JJTH, van 't Veer C, van der Poll T. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. This issue, pp 122-32.
© 2010 International Society on Thrombosis and Haemostasis.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21210950      PMCID： PMC3034136          DOI： 10.1111/j.1538-7836.2010.04111.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN： 1538-7836            Impact factor:   5.824


  17 in total

1.  Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.

Authors:  Anita W Rijneveld; Sebastiaan Weijer; Paul Bresser; Sandrine Florquin; George P Vlasuk; William E Rote; C Arnold Spek; Pieter H Reitsma; Jaring S van der Zee; Marcel Levi; Tom van der Poll
Journal:  Crit Care Med       Date:  2006-06       Impact factor: 7.598

Review 2.  Community-acquired pneumonia: the U.S. perspective.

Authors:  Michael S Niederman
Journal:  Semin Respir Crit Care Med       Date:  2009-03-18       Impact factor: 3.119

3.  Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases.

Authors:  Steffen Massberg; Lenka Grahl; Marie-Luise von Bruehl; Davit Manukyan; Susanne Pfeiler; Christian Goosmann; Volker Brinkmann; Michael Lorenz; Kiril Bidzhekov; Avinash B Khandagale; Ildiko Konrad; Elisabeth Kennerknecht; Katja Reges; Stefan Holdenrieder; Siegmund Braun; Christoph Reinhardt; Michael Spannagl; Klaus T Preissner; Bernd Engelmann
Journal:  Nat Med       Date:  2010-08-01       Impact factor: 53.440

4.  Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody.

Authors:  F B Taylor; A Chang; W Ruf; J H Morrissey; L Hinshaw; R Catlett; K Blick; T S Edgington
Journal:  Circ Shock       Date:  1991-03

5.  Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

Authors:  E Abraham; K Reinhart; P Svoboda; A Seibert; D Olthoff; A Dal Nogare; R Postier; G Hempelmann; T Butler; E Martin; C Zwingelstein; S Percell; V Shu; A Leighton; A A Creasey
Journal:  Crit Care Med       Date:  2001-11       Impact factor: 7.598

Review 6.  Of mice and men: innate immunity in pneumococcal pneumonia.

Authors:  Esther Calbo; Javier Garau
Journal:  Int J Antimicrob Agents       Date:  2009-12-14       Impact factor: 5.283

7.  Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial.

Authors:  Edward Abraham; Konrad Reinhart; Steven Opal; Ignace Demeyer; Christopher Doig; Angel López Rodriguez; Richard Beale; Petr Svoboda; Pierre Francois Laterre; Stuart Simon; Bruce Light; Herbert Spapen; Judy Stone; Allan Seibert; Claus Peckelsen; Cathy De Deyne; Russell Postier; Ville Pettilä; Charles L Sprung; Antonio Artigas; Sandra R Percell; Vincent Shu; Christian Zwingelstein; Jeffrey Tobias; Lona Poole; James C Stolzenbach; Abla A Creasey
Journal:  JAMA       Date:  2003-07-09       Impact factor: 56.272

8.  Depletion of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: evidence supporting a physiologic role for EPI as a natural anticoagulant.

Authors:  P M Sandset; B J Warn-Cramer; L V Rao; S L Maki; S I Rapaport
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

9.  Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.

Authors:  A A Creasey; A C Chang; L Feigen; T C Wün; F B Taylor; L B Hinshaw
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

Review 10.  Beyond antibiotics in severe community-acquired pneumonia: the role and rationale for tissue factor pathway inhibition.

Authors:  Pierre-Francois Laterre
Journal:  Crit Care       Date:  2008-11-26       Impact factor: 9.097
View more
  2 in total

Review 1.  Thrombocytopenia in Dengue: Interrelationship between Virus and the Imbalance between Coagulation and Fibrinolysis and Inflammatory Mediators.

Authors:  Elzinandes Leal de Azeredo; Robson Q Monteiro; Luzia Maria de-Oliveira Pinto
Journal:  Mediators Inflamm       Date:  2015-04-27       Impact factor: 4.711

2.  Regulation of TFPIα expression by miR-27a/b-3p in human endothelial cells under normal conditions and in response to androgens.

Authors:  Ana B Arroyo; Salam Salloum-Asfar; Carlos Pérez-Sánchez; Raúl Teruel-Montoya; Silvia Navarro; Nuria García-Barberá; Ginés Luengo-Gil; Vanessa Roldán; John-Bjarne Hansen; Chary López-Pedrera; Vicente Vicente; Rocío González-Conejero; Constantino Martínez
Journal:  Sci Rep       Date:  2017-02-27       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.